ストックスクリーナーアプリを入手
4.67
2.51%
-0.12
アフターアワーズ：
4.68
0.010
+0.21%
Coya Therapeutics Inc (COYA) 最新ニュース
COYA|Coya Therapeutics Inc|Price:4.790|Chg%:+0.120 - TradingKey
Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics Inc (COYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR) - The Globe and Mail
Coya Therapeutics (NASDAQ:COYA) Posts Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Form 8K Coya Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria
Coya Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Coya Therapeutics posts investor presentation on Treg-directed combination therapy for neurodegenerative diseases - Bitget
Coya Therapeutics reports Q2 2026 net loss $6.64M, cash $43.2M; ALSTARS Phase 2 enrollment on track - TradingView
Coya Therapeutics Q2 net loss widens as R&D costs rise - TradingView
Coya Therapeutics Reports Q2 Net Loss of $6.6 Million - Quiver Quantitative
Coya Therapeutics (NASDAQ: COYA) details Q2 2026 results, ALS Fast Track and cash runway - Stock Titan
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - Business Wire
Coya Therapeutics (NASDAQ:COYA): What Could Today’s Update Reveal About Clinical Execution And Funding Priorities? - Kalkine Media
Coya Therapeutics (COYA) Earnings Date and Reports 2026 - MarketBeat
IMDX Stock Price and Chart — NASDAQ:IMDX - tradingview.com
Coya Therapeutics (NASDAQ: COYA) names Mark Pavao to its Audit Committee - Stock Titan
Coya Therapeutics, Inc. Appoints Mark H. Pavao to Its Audit Committee of Board, Effective August 7, 2026 - marketscreener.com
Coya Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Treg Therapy Market - Future Market Insights
Coya Therapeutics (COYA) Expected to Release Earnings on Tuesday - MarketBeat
Avoiding Lag: Real-Time Signals in (COYA) Movement - Stock Traders Daily
Coya Therapeutics (COYA) Holds Steady at $4.0 Amid Key Support and Resistance BattleMomentum Surge Alerts - dars.gov.et
Coya Therapeutics (NASDAQ: COYA) holder discloses 3.3% stake in amended filing - Stock Titan
Coya Therapeutics Inc (COYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Coya Therapeutics Inc (COYA) Balance Sheet - TradingKey
Coya Therapeutics Inc (COYA) Cash Flow - TradingKey
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Coya Therapeutics Inc (COYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
COYA|Coya Therapeutics Inc|Price:4.250|Chg%:-0.130 - TradingKey
Coya Therapeutics Inc (COYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Coya Therapeutics Inc (COYA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Coya Therapeutics Market Sentiment - Benzinga España
Coya Therapeutics Inc (COYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Coya Therapeutics Inc (COYA) Income Statement - TradingKey
Coya Therapeutics, Inc. Revenue Breakdown – NASDAQ:COYA - TradingView
Coya Therapeutics (NASDAQ:COYA) Trading Up 0.2%Should You Buy? - MarketBeat
Discipline and Rules-Based Execution in COYA Response - Stock Traders Daily
Price to book forward of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
Price to earnings forward of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
Price to sales forward of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
Coya Therapeutics (COYA) Dips 1.3% as Stock Tests Key Support LevelsBear Pennant - dars.gov.et
Houston ALS Biotech Coya Eyes 2028 Approval Path - Streetwise Reports
Coya Targets ALS Trial Readout in Q1 2027, H.C. Wainwright Sets US$18 Price Target - Streetwise Reports
Coya Therapeutics (COYA) Holds Steady at $5.26 as Trading Range NarrowsIV Crush Alert - dars.gov.et
Coya Therapeutics(COYA) Stock Options Chain | Quotes & News - Moomoo
Coya Therapeutics (COYA) Slips 1.87% as Stock Tests Key Support Near $5.00Triple Top - dars.gov.et
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease - AOL.com
Analysts Are Bullish on Top Healthcare Stocks: Coya Therapeutics, Inc. (COYA), Palisade Bio (PALI) - The Globe and Mail
COYA Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline AdvancesProfitability Analysis - dars.gov.et
Roth MKM Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Coya Therapeutics Dips 2.3% as Stock Tests Key Support at $5.42Max Pain Level - dars.gov.et
Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Behavioral Patterns of COYA and Institutional Flows - Stock Traders Daily
Coya Therapeutics, Inc. Actuals & Estimates (NASDAQ:COYA) - TradingView
Coya Therapeutics, Inc. Actuals & Estimates (BOATS:COYA) - TradingView
Coya Therapeutics Price Target Maintained With a $14.00/Share by Chardan Capital - Moomoo
H.C. Wainwright Remains a Buy on Coya Therapeutics, Inc. (COYA) - The Globe and Mail
Coya Therapeutics, Inc. Reports 2026 Annual Meeting Results and Company Information (NASDAQ: COYA) - Minichart
Coya Therapeutics Shareholders Back Board, Auditor at Meeting - TipRanks
Coya Therapeutics (NASDAQ: COYA) shareholders back board nominees and 2026 auditor - Stock Titan
COYA Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Coya Therapeutics (COYA) Investor update Summary - Quartr
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):